---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-084969"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:53:33.901981+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q3 update: expands tecarfarin to LVAD/APS, cash $9.1M

## Summary
- Expanded tecarfarin development beyond ESKD with AFib to include LVAD and APS, adding $1.5B annual U.S. market opportunity.
- Total addressable market for tecarfarin now over $2 billion annually in the U.S.
- Q3 2023 operating expenses (non-cash) totaled $989,000; cash used in operations $628,000.
- Cash balance as of Sept 30, 2023 was $9.1 million, providing flexibility to initiate pivotal trial in 2024.
- Completed $7.5 million private placement at $1.75/share in July 2023.

## SEC filing metadata
- accession: 0001213900-23-084969
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023084969/0001213900-23-084969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023084969/ea187953-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-084969
- JSON: https://secwatch.observer/filing/0001213900-23-084969.json
- Plain text: https://secwatch.observer/filing/0001213900-23-084969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.